Section Arrow
JANX.NASDAQ
- Janux Therapeutics
Quotes are at least 15-min delayed:2025/09/01 15:11 EDT
Regular Hours
Last
 22.72
-0.33 (-1.43%)
Day High 
23.63 
Prev. Close
23.05 
1-M High
26.5 
Volume 
456.35K 
Bid
22.7
Ask
22.74
Day Low
22.46 
Open
23.1 
1-M Low
21.9707 
Market Cap 
1.39B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 24.16 
20-SMA 24.05 
50-SMA 24.5 
52-W High 71.71 
52-W Low 21.9707 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.81/-2.83
Enterprise Value
1.41B
Balance Sheet
Book Value Per Share
16.48
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
10.59M
Operating Revenue Per Share
0.14
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed:2025/09/01 15:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T CellEngagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with atumor antigen-binding domain and a costimulatory CD28 binding domain.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.